Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Viral vectors for dendritic cell-based immunotherapy.

J Humrich1, L Jenne

  • 1Department of Dermatology, University of Erlangen, Hartmannstrasse 14, 91052 Erlangen, Germany.

Current Topics in Microbiology and Immunology
|June 12, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-term (6 and 12 months) follow-up of two prospective, randomized, controlled phase III trials of photodynamic therapy with BF-200 ALA and methyl aminolaevulinate for the treatment of actinic keratosis.

The British journal of dermatology·2012
Same author

Photodynamic therapy with BF-200 ALA for the treatment of actinic keratosis: results of a multicentre, randomized, observer-blind phase III study in comparison with a registered methyl-5-aminolaevulinate cream and placebo.

The British journal of dermatology·2011
Same author

The highly attenuated vaccinia virus strain modified virus Ankara induces apoptosis in melanoma cells and allows bystander dendritic cells to generate a potent anti-tumoral immunity.

Clinical and experimental immunology·2006
Same author

[Regulatory T cells in rheumatic diseases].

Deutsche medizinische Wochenschrift (1946)·2006
Same author

Successful treatment of therapy-resistant chronic vegetating pyoderma gangrenosum with infliximab (chimeric antitumour necrosis factor antibody).

The British journal of dermatology·2004
Same author

Interaction of cutaneous lymphoma cells with reactive T cells and dendritic cells: implications for dendritic cell-based immunotherapy.

The British journal of dermatology·2003
Same journal

Correction to: Resolution of Skeletal Muscle Inflammation: Role of Specialized Pro-resolving Lipid Mediators in the Recovery from Exercise, Injury, and Disease.

Current topics in microbiology and immunology·2026
Same journal

Resolution Biology in Soft Tissue Joint Disease.

Current topics in microbiology and immunology·2026
Same journal

A 25+ Year Journey on Yeast-Regulated Cell Death Research.

Current topics in microbiology and immunology·2026
Same journal

Adoptive T-Cell Immunotherapy.

Current topics in microbiology and immunology·2026
Same journal

Resolution Pharmacology Targeting the Melanocortin System.

Current topics in microbiology and immunology·2026
Same journal

Resolution of Skeletal Muscle Inflammation: Role of Specialized Pro-resolving Lipid Mediators in the Recovery from Exercise, Injury, and Disease.

Current topics in microbiology and immunology·2026
See all related articles

Viral vectors offer a promising alternative for engineering dendritic cells (DCs) for cancer immunotherapy by enabling broader antigen presentation. However, understanding viral vector interactions with DCs is crucial for optimizing this approach.

Area of Science:

  • Immunology
  • Oncology
  • Biotechnology

Background:

  • Dendritic cells (DCs) are key antigen-presenting cells crucial for initiating immune responses against various antigens, including those found in tumors.
  • Advances in generating DCs and identifying tumor-associated antigens (TAA) have spurred interest in DC-based cancer immunotherapies.
  • Current methods like peptide pulsing and whole tumor cell loading have limitations, including antigen presentation longevity, MHC restriction, standardization issues, and tumor cell availability.

Purpose of the Study:

  • To review the use of viral vectors for ex vivo transduction of dendritic cells (DCs) to express tumor-associated antigens (TAA).
  • To explore the potential of viral vectors for achieving both MHC class I and MHC class II-restricted presentation of tumor antigens.
  • To discuss the advantages and disadvantages of different viral vectors currently employed in DC-based cancer immunotherapy.

Related Experiment Videos

Main Methods:

  • Review of existing literature on viral vector-mediated transduction of dendritic cells for cancer immunotherapy.
  • Analysis of studies reporting transduction efficiencies and interactions between viral vectors and DCs.
  • Evaluation of the impact of viral vector transduction on DC function and immune response induction.

Main Results:

  • Viral vectors provide a method for ex vivo genetic modification of DCs to express TAA, facilitating both MHC class I and MHC class II-restricted antigen presentation.
  • While high transduction efficiencies have been reported for various viral vectors, some vectors interfere with critical DC functions.
  • Despite challenges, promising results have been achieved with different viral vector systems in preclinical and clinical settings.

Conclusions:

  • Viral vector-transduced DCs represent an attractive strategy for cancer immunotherapy, overcoming limitations of traditional antigen loading methods.
  • Further research is needed to optimize viral vector design and understand their interactions with DCs to mitigate adverse effects on DC function.
  • The field shows promise, with ongoing development of various vectors offering potential for effective anti-tumoral immune responses.